250 related articles for article (PubMed ID: 23054646)
1. Splicing factor mutations in myelodysplasia.
Ogawa S
Int J Hematol; 2012 Oct; 96(4):438-42. PubMed ID: 23054646
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.
Je EM; Yoo NJ; Kim YJ; Kim MS; Lee SH
Int J Cancer; 2013 Jul; 133(1):260-5. PubMed ID: 23280334
[TBL] [Abstract][Full Text] [Related]
5. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
6. Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.
Hirabayashi S; Flotho C; Moetter J; Heuser M; Hasle H; Gruhn B; Klingebiel T; Thol F; Schlegelberger B; Baumann I; Strahm B; Stary J; Locatelli F; Zecca M; Bergstraesser E; Dworzak M; van den Heuvel-Eibrink MM; De Moerloose B; Ogawa S; Niemeyer CM; Wlodarski MW;
Blood; 2012 Mar; 119(11):e96-9. PubMed ID: 22238327
[TBL] [Abstract][Full Text] [Related]
7. Frequent pathway mutations of splicing machinery in myelodysplasia.
Yoshida K; Sanada M; Shiraishi Y; Nowak D; Nagata Y; Yamamoto R; Sato Y; Sato-Otsubo A; Kon A; Nagasaki M; Chalkidis G; Suzuki Y; Shiosaka M; Kawahata R; Yamaguchi T; Otsu M; Obara N; Sakata-Yanagimoto M; Ishiyama K; Mori H; Nolte F; Hofmann WK; Miyawaki S; Sugano S; Haferlach C; Koeffler HP; Shih LY; Haferlach T; Chiba S; Nakauchi H; Miyano S; Ogawa S
Nature; 2011 Sep; 478(7367):64-9. PubMed ID: 21909114
[TBL] [Abstract][Full Text] [Related]
8. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
Damm F; Kosmider O; Gelsi-Boyer V; Renneville A; Carbuccia N; Hidalgo-Curtis C; Della Valle V; Couronné L; Scourzic L; Chesnais V; Guerci-Bresler A; Slama B; Beyne-Rauzy O; Schmidt-Tanguy A; Stamatoullas-Bastard A; Dreyfus F; Prébet T; de Botton S; Vey N; Morgan MA; Cross NC; Preudhomme C; Birnbaum D; Bernard OA; Fontenay M;
Blood; 2012 Apr; 119(14):3211-8. PubMed ID: 22343920
[TBL] [Abstract][Full Text] [Related]
9. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
Boultwood J; Dolatshad H; Varanasi SS; Yip BH; Pellagatti A
Adv Biol Regul; 2014 Jan; 54():153-61. PubMed ID: 24080589
[TBL] [Abstract][Full Text] [Related]
10. Spliceosome mutations in hematopoietic malignancies.
Hahn CN; Scott HS
Nat Genet; 2011 Dec; 44(1):9-10. PubMed ID: 22200771
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Malcovati L; Papaemmanuil E; Bowen DT; Boultwood J; Della Porta MG; Pascutto C; Travaglino E; Groves MJ; Godfrey AL; Ambaglio I; Gallì A; Da Vià MC; Conte S; Tauro S; Keenan N; Hyslop A; Hinton J; Mudie LJ; Wainscoat JS; Futreal PA; Stratton MR; Campbell PJ; Hellström-Lindberg E; Cazzola M;
Blood; 2011 Dec; 118(24):6239-46. PubMed ID: 21998214
[TBL] [Abstract][Full Text] [Related]
12. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.
Taylor J; Lee SC
Genes Chromosomes Cancer; 2019 Dec; 58(12):889-902. PubMed ID: 31334570
[TBL] [Abstract][Full Text] [Related]
13. [Point mutations of genes encoding proteins involvedin RNA splicing in patients with myelodysplastic syndromes].
Barańska M; Czerwińska-Rybak J; Gil L; Komarnicki M
Pol Merkur Lekarski; 2015 Jan; 38(223):5-10. PubMed ID: 25763580
[TBL] [Abstract][Full Text] [Related]
14. [Deregulated splicing machinery in myelodysplastic syndromes].
Ogawa S
Rinsho Ketsueki; 2012 May; 53(5):493-6. PubMed ID: 22728550
[No Abstract] [Full Text] [Related]
15. Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling.
Taskesen E; Havermans M; van Lom K; Sanders MA; van Norden Y; Bindels E; Hoogenboezem R; Reinders MJ; Figueroa ME; Valk PJ; Löwenberg B; Melnick A; Delwel R
Blood; 2014 May; 123(21):3327-35. PubMed ID: 24668493
[TBL] [Abstract][Full Text] [Related]
16. The molecular pathogenesis of the myelodysplastic syndromes.
Pellagatti A; Boultwood J
Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia.
Wong JJ; Lau KA; Pinello N; Rasko JE
Cancer Sci; 2014 Nov; 105(11):1457-63. PubMed ID: 25220401
[TBL] [Abstract][Full Text] [Related]
18. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.
Armstrong RN; Steeples V; Singh S; Sanchi A; Boultwood J; Pellagatti A
Adv Biol Regul; 2018 Jan; 67():13-29. PubMed ID: 28986033
[TBL] [Abstract][Full Text] [Related]
19. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
Qian J; Yao DM; Lin J; Qian W; Wang CZ; Chai HY; Yang J; Li Y; Deng ZQ; Ma JC; Chen XX
PLoS One; 2012; 7(9):e45760. PubMed ID: 23029227
[TBL] [Abstract][Full Text] [Related]
20. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
